Prokidney (PROK) Cash from Investing Activities (2021 - 2026)
Prokidney (PROK) reported Cash from Investing Activities of $34.8 million for Q1 2026, up 23.11% year-over-year from $28.3 million in Q1 2025, and up 23.97% quarter-over-quarter from $28.1 million in Q4 2025.
Prokidney (PROK) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Prokidney (PROK) has 6 years of Cash from Investing Activities data on file, last reported at $34.8 million in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at $34.8 million, up 23.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $110.5 million (up 1239.68% YoY), and the FY2025 annual result was $104.0 million, up 409.28% from the prior year.
- Cash from Investing Activities advanced to $34.8 million in Q1 2026 per PROK's latest filing, from $28.1 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $58.4 million in Q1 2024 and troughed at -$192.6 million in Q1 2023.
- A 5-year average of -$10.1 million and a median of -$207000.0 in 2022 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities slumped 31221.57% in 2023, then jumped 317.21% in 2024.
- A 5-year view of Cash from Investing Activities shows it stood at -$306000.0 in 2022, then tumbled by 31221.57% to -$95.8 million in 2023, then surged by 115.73% to $15.1 million in 2024, then soared by 86.29% to $28.1 million in 2025, then grew by 23.97% to $34.8 million in 2026.
- Business Quant data shows PROK's Cash from Investing Activities at $34.8 million in Q1 2026, $28.1 million in Q4 2025, and $29.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Prokidney | 259.01 Mn | 1.55 Bn | - | 34.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.83 Mn |
| Mar 31, 2026 | 34.83 Mn |
| Dec 31, 2025 | 28.09 Mn |
| Dec 31, 2025 | 28.09 Mn |
| Sep 30, 2025 | 29.02 Mn |
| Sep 30, 2025 | 29.02 Mn |
| Jun 30, 2025 | 18.57 Mn |
| Jun 30, 2025 | 18.57 Mn |
| Mar 31, 2025 | 28.29 Mn |
| Mar 31, 2025 | 28.29 Mn |
| Dec 31, 2024 | 15.08 Mn |
| Dec 31, 2024 | 15.08 Mn |
| Sep 30, 2024 | -81.64 Mn |
| Sep 30, 2024 | -81.64 Mn |
| Jun 30, 2024 | 28.57 Mn |
| Jun 30, 2024 | 28.57 Mn |
| Mar 31, 2024 | 58.40 Mn |
| Mar 31, 2024 | 58.40 Mn |
| Dec 31, 2023 | -95.84 Mn |
| Dec 31, 2023 | -95.84 Mn |